IRVINE, Calif., Oct. 16, 2020 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, today reported financial results for the fiscal quarter ended August 31, 2020.
Original post:
Biomerica Reports Fiscal 2021 1st Quarter Financial Results
MELBOURNE, Australia, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT, Nasdaq: OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progressive retinal diseases, today announces the pricing of its initial public offering in the United States (the “Offering”) of 8,563,300 American Depositary Shares (“ADS”), representing 68,506,400 ordinary shares, at an initial public offering price of US$13.50 per ADS, before underwriting discounts and commissions. In addition, and in lieu of ADSs, the Company offered and sold to certain investors pre-funded warrants to purchase 936,700 ADSs at a public offering price of US$13.49999 per pre-funded warrant, which represents the initial public offering price per ADS, minus the US$0.00001 per ADS exercise price of each pre-funded warrant. The aggregate gross proceeds to the Company are expected to be approximately US$128.2 million. The Company has also granted the underwriters a 30-day option to purchase up to an additional 1,425,000 ADSs at the initial public offering price per ADS less underwriting discounts and commissions. The ADSs are expected to begin trading on the Nasdaq Global Select Market on October 16, 2020 under the ticker symbol “OPT.” The Offering is expected to close on or about October 20, 2020, subject to the satisfaction of customary closing conditions.
Link:
Opthea Announces Pricing of Initial Public Offering in the United States
VANCOUVER, British Columbia, Oct. 16, 2020 (GLOBE NEWSWIRE) -- MYDECINE INNOVATIONS GROUP, INC., (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”) is pleased to announce the appointment of UK-based Boustead Capital Markets LLP (“Boustead”) to commence the dual listing process on the London Stock Exchange (“LSE” or the “Exchange”) for the admission of the Company’s common shares to the Standard Segment of the Official List’s Main Market.
Read the rest here:
Mydecine Innovations Group Appoints Boustead Capital Markets LLP as Financial Advisor for its Planned Dual Listing on the London Stock Exchange
– Agios Continues to Advance Two Phase 3 Combination Trials of TIBSOVO® in Newly Diagnosed AML Patients –
Continue reading here:
Agios Announces Withdrawal of European Marketing Authorization Application for TIBSOVO® as a Treatment for Relapsed or Refractory IDH1-mutant Acute...
DEER PARK, Ill., Oct. 16, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced the closing of its previously announced offering of 3,220,000 shares of common stock at a public offering price of $7.00 per share. The total offering included 420,000 shares sold as a result of the underwriter’s exercise of its overallotment option in full.
Read more here:
Eton Pharmaceuticals Announces Closing of Public Offering
WALTHAM, Mass., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis and other diseases caused by nonsense mutations limiting production of functional proteins, today announced that Professor Eitan Kerem, M.D. has joined the Company as a Senior Consultant. Dr. Kerem will continue to advise on our cystic fibrosis program focusing on strategic leadership, cystic fibrosis medical safety review, and medical communications, as well as liaising with patient advocacy groups and regulatory authorities.
Excerpt from:
Globally Renowned Cystic Fibrosis Expert, Dr. Eitan Kerem, Joins Eloxx Pharmaceuticals as a Senior Consultant
Company announcement no. 32 - 20 14 September 2020
See the article here:
Private placement of existing shares and major shareholder announcement
SPARTA, N.J., Sept. 14, 2020 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on developing its clinically-validated and patent-protected PLxGuard™ delivery system to provide more effective and safer products, VAZALORE™ 325 mg and VAZALORE™ 81 mg (referred to together as “VAZALORE”™), announced today that Natasha Giordano, President and Chief Executive Officer, and Rita O’Connor, Chief Financial Officer, will present virtually at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit as follows:
The rest is here:
PLx Pharma Inc. to Present Virtually at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
- Lead product candidate, SB206 currently being evaluated in B-SIMPLE4 pivotal Phase 3 study in molluscum contagiosum with topline data targeted for Q2 2021 -
Excerpt from:
Novan Provides Pipeline and Priority Development Programs Update
